Logo image of IBO

IMPACT BIOMEDICAL INC (IBO) Stock Fundamental Analysis

NYSEARCA:IBO - US45259L2051 - Common Stock

0.5739 USD
-0.01 (-2.3%)
Last: 8/29/2025, 10:42:07 AM
Fundamental Rating

0

Overall IBO gets a fundamental rating of 0 out of 10. We evaluated IBO against 193 industry peers in the Pharmaceuticals industry. IBO has a bad profitability rating. Also its financial health evaluation is rather negative. IBO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

IBO had negative earnings in the past year.
In the past year IBO has reported a negative cash flow from operations.
IBO Yearly Net Income VS EBIT VS OCF VS FCFIBO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -201.86%, IBO is not doing good in the industry: 90.67% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -201.86%
ROE N/A
ROIC N/A
ROA(3y)-48.88%
ROA(5y)N/A
ROE(3y)-207.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBO Yearly ROA, ROE, ROICIBO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

IBO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBO Yearly Profit, Operating, Gross MarginsIBO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K

0

2. Health

2.1 Basic Checks

The number of shares outstanding for IBO remains at a similar level compared to 1 year ago.
The debt/assets ratio for IBO is higher compared to a year ago.
IBO Yearly Shares OutstandingIBO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M 10M
IBO Yearly Total Debt VS Total AssetsIBO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

IBO has an Altman-Z score of -5.85. This is a bad value and indicates that IBO is not financially healthy and even has some risk of bankruptcy.
IBO has a Altman-Z score of -5.85. This is in the lower half of the industry: IBO underperforms 61.14% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.85
ROIC/WACCN/A
WACCN/A
IBO Yearly LT Debt VS Equity VS FCFIBO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 0.06 indicates that IBO may have some problems paying its short term obligations.
IBO's Current ratio of 0.06 is on the low side compared to the rest of the industry. IBO is outperformed by 97.41% of its industry peers.
A Quick Ratio of 0.04 indicates that IBO may have some problems paying its short term obligations.
The Quick ratio of IBO (0.04) is worse than 97.41% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.04
IBO Yearly Current Assets VS Current LiabilitesIBO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

0

3. Growth

3.1 Past

IBO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -509.26%.
EPS 1Y (TTM)-509.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1423.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IBO Yearly Revenue VS EstimatesIBO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 10K 20K 30K 40K

0

4. Valuation

4.1 Price/Earnings Ratio

IBO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBO Price Earnings VS Forward Price EarningsIBO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBO Per share dataIBO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

IBO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IMPACT BIOMEDICAL INC

NYSEARCA:IBO (8/29/2025, 10:42:07 AM)

0.5739

-0.01 (-2.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners3.19%
Inst Owner Change51.52%
Ins Owners3.7%
Ins Owner Change-1185.52%
Market Cap7.00M
AnalystsN/A
Price TargetN/A
Short Float %2.18%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 999.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0
BVpS-0.85
TBVpS-2.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -201.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.88%
ROA(5y)N/A
ROE(3y)-207.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.04
Altman-Z -5.85
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-509.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1423.03%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.46%
OCF growth 3YN/A
OCF growth 5YN/A